Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on [...]